TAUNS Laboratories,Inc.
197A・Standard Market・Pharmaceuticals
Governance
The company has a Board of Corporate Auditors and a Board of Directors composed of 6 directors (including 2 outside directors), and has established a voluntary Nomination and Compensation Advisory Committee (a majority of members are outside directors, and the chairperson is an independent outside director). EY Shinnihon LLC serves as the accounting auditor.
Risk Management
The company has established a Risk & Compliance Committee chaired by the Representative Director and President, which meets in principle at least once per quarter (held 5 times in FY2025 (ended June 2025)). The committee manages diverse risks including compliance, personal information, and security, while the Internal Audit Office (2 members), reporting directly to the Representative Director and President, conducts operational audits covering all departments, forming a three-way audit structure together with the Audit & Supervisory Board Members and the accounting auditor.
Shareholder Returns
For FY2026 (ending June 2026), the annual dividend forecast is ¥28 per share (¥14 already paid at the second-quarter end, with ¥14 planned at year-end), maintaining the same amount as the previous period. The company continues its progressive dividend policy and retains share buybacks as part of its policy. There is no revision from the previous dividend forecast.
Dividend Policy
During the medium-term management plan period from FY2026 (ending June 2026) to FY2030 (ending June 2030), the company intends to implement a progressive dividend policy starting from a base of ¥28. For FY2026 (ending June 2026), ¥14 was already paid at the second-quarter end, with ¥14 planned at year-end, for a forecasted annual total of ¥28. This maintains the same level as the previous period (FY2025, ended June 2025), which totaled ¥28 annually (ordinary dividend of ¥18 plus a founding anniversary commemorative dividend of ¥10). In addition to the dividend policy, the company intends to implement share buybacks as necessary, taking into account the business environment and stock market trends. There is no revision from the most recently announced dividend forecast.
ESG
Under the slogan "For a secure everyday life through diagnostic technology," the company has identified and disclosed materiality items including environmental consideration (93.2% hybrid vehicle ratio for company-owned vehicles), contribution to global health (overseas distributors in 27 countries), quality control (zero major findings from regulatory authorities), and human capital (100% male childcare leave take-up rate, 15.8% female manager ratio). The materiality items were resolved following deliberation by the Board of Directors, with reference to international guidelines such as the SDGs, GRI, and SASB.
Last updated: September 25, 2025